A 6-month follow-up study on response and relapse rates following an acute trial of repetitive transcranial magnetic stimulation in patients with major depression.


Journal

CNS spectrums
ISSN: 1092-8529
Titre abrégé: CNS Spectr
Pays: United States
ID NLM: 9702877

Informations de publication

Date de publication:
02 2022
Historique:
pubmed: 5 9 2020
medline: 7 5 2022
entrez: 5 9 2020
Statut: ppublish

Résumé

Little is known about the post-acute effects of repetitive transcranial magnetic stimulation (rTMS) in patients with major depression. The present study focused on the 6-month follow-up of a sample of patients with major depression, after the completion of an acute 4 weeks rTMS trial, with the aim of evaluating response (in terms of sustained and late response) and relapse rates. Following the completion of an acute trial of rTMS (T0-T4), 31 drug-resistant depressed patients (bipolar or unipolar) entered a naturalistic follow-up period of 6 months, with three timepoints (T5, T6, and T7) during which they were assessed with the Hamilton Depression Rating Scale and the Young Mania Rating Scale. Results showed that in the 6 months following an acute transcranial magnetic stimulation (TMS) trial, a higher rate of late responders was observed among previously acute TMS nonresponders (63.64%, 7 out of 11) compared to the rate of relapse among those who had acutely responded to TMS (10%, 2 out of 20). In addition, an overall high rate of maintained response (90%) was observed. Present findings seem to support the possibility of obtaining a clinical response also after the end of an acute TMS trial in patients with major depression. The concomitant low rate of relapse observed at the end of follow-up along with a high rate of maintained response provides further support to the post-acute efficacy of TMS. Nonetheless, further controlled studies, with larger samples and longer follow-up observation, are needed to confirm the reported results.

Sections du résumé

BACKGROUND
Little is known about the post-acute effects of repetitive transcranial magnetic stimulation (rTMS) in patients with major depression. The present study focused on the 6-month follow-up of a sample of patients with major depression, after the completion of an acute 4 weeks rTMS trial, with the aim of evaluating response (in terms of sustained and late response) and relapse rates.
METHODS
Following the completion of an acute trial of rTMS (T0-T4), 31 drug-resistant depressed patients (bipolar or unipolar) entered a naturalistic follow-up period of 6 months, with three timepoints (T5, T6, and T7) during which they were assessed with the Hamilton Depression Rating Scale and the Young Mania Rating Scale.
RESULTS
Results showed that in the 6 months following an acute transcranial magnetic stimulation (TMS) trial, a higher rate of late responders was observed among previously acute TMS nonresponders (63.64%, 7 out of 11) compared to the rate of relapse among those who had acutely responded to TMS (10%, 2 out of 20). In addition, an overall high rate of maintained response (90%) was observed.
CONCLUSION
Present findings seem to support the possibility of obtaining a clinical response also after the end of an acute TMS trial in patients with major depression. The concomitant low rate of relapse observed at the end of follow-up along with a high rate of maintained response provides further support to the post-acute efficacy of TMS. Nonetheless, further controlled studies, with larger samples and longer follow-up observation, are needed to confirm the reported results.

Identifiants

pubmed: 32883389
doi: 10.1017/S1092852920001807
pii: S1092852920001807
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

93-98

Auteurs

Chiara Arici (C)

Department of Mental Health and Addiction, ASST Vimercate, Vimercate, Italy.

Beatrice Benatti (B)

Department of Biomedical and Clinical Sciences 'Luigi Sacco', Department of Mental Health, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.
Department of Health Sciences, 'Aldo Ravelli' Research Center for Neurotechnology and Experimental Brain Therapeutics, University of Milan Medical School, Milan, Italy.

Rita Cafaro (R)

Department of Biomedical and Clinical Sciences 'Luigi Sacco', Department of Mental Health, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.

Laura Cremaschi (L)

Department of Mental Health and Addiction, ASST Papa Giovanni XXIII, Bergamo, Italy.

Luca Degoni (L)

Department of Psychiatry, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, Milano, Italy.

Sara Pozzoli (S)

Department of Psychiatry, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, Milano, Italy.

Lucio Oldani (L)

Department of Psychiatry, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, Milano, Italy.

Laura Molteni (L)

Department of Biomedical and Clinical Sciences 'Luigi Sacco', Department of Mental Health, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.

Federica Giorgetti (F)

Department of Biomedical and Clinical Sciences 'Luigi Sacco', Department of Mental Health, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.

Alberto Priori (A)

Department of Health Sciences, 'Aldo Ravelli' Research Center for Neurotechnology and Experimental Brain Therapeutics, University of Milan Medical School, Milan, Italy.
Department of Health Sciences, San Paolo Hospital, University of Milan, Milan, Italy.

Caterina Viganò (C)

Department of Biomedical and Clinical Sciences 'Luigi Sacco', Department of Mental Health, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.

Bernardo Dell'Osso (B)

Department of Biomedical and Clinical Sciences 'Luigi Sacco', Department of Mental Health, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.
Department of Health Sciences, 'Aldo Ravelli' Research Center for Neurotechnology and Experimental Brain Therapeutics, University of Milan Medical School, Milan, Italy.
Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH